The JX-594 and PD-1 inhibitor combination upregulated M1 tumor-associated macrophages (TAMs), with a 2.3-fold increase compared with PD-1 inhibitor monotherapy, and downregulated M2 TAMs (Fig. 3). This evidence concerns the gene PDCD1 and neoplasm.